Abstract
The selective neurotoxin 6-hydroxydopa (6-OHDOPA) was developed because of the correct assumption that it could, with some advantage, replicate actions of the newly discovered selective neurotoxin 6-hydroxydopamine (6-OHDA). 6-OHDOPA is a highly selective neurotoxin, targeting primarily noradrenergic nerves. By this, 6-OHDOPA is able to produce a chemical sympathectomy by destroying axonal tracts from sympathetic paraganglia as well as noradrenergic nerve terminals in peripheral organs and tissues. The sympathectomy can be produced when 6-OHDOPA is administered to either perinatal or adult animals. The effect, however, is not permanent, as the sympathetic nervous system fully regenerate to reinnervate the periphery in approximately 6 weeks. In the central nervous system (CNS), peripherally administered 6-OHDOPA has relative selectivity for noradrenergic neurons, predominately producing destructive effects on the locus coeruleus, the largest noradrenergic nucleus in the brain, having long axonal projections to forebrain, hippocampus, and cerebellum. Administered in high dose to adult mice or rats, 6-OHDA produces near total noradrenergic denervation of hippocampus, approximately 90% noradrenergic denervation of neocortex and cerebellum. When administered in high dose to perinatal rodents, a similar noradrenergic denervation spectrum is seen for hippocampus, neocortex, and cerebellum, and overtly damages neuronal perikaryal in the distal locus coeruleus. However, in time regenerated axons from locus coeruleus regrow short axons to produce neoinnervation and ultimate hyperinnervation of hindbrain regions, pons and medulla, and two-fold hyperinnervation of cerebellum. Effects of 6-OHDOPA on other noradrenergic nuclei in the brain are seemingly minor. An extremely high dose of 6-OHDOPA produces lethality, thus giving limitation to the practicality of 6-OHDOPA for a variety of studies.
6-OHDOPA was subsequently found to be an excitotoxin at non-NMDA (N-methyl-D-aspartate) receptors, likely because of it spontaneous generation of 6-OHDOPA-p-quinone, dopachrome, and dopaminechrome. As such, 6-OHDOPA is more excitotoxic than the endogenous NMDA receptor agonist glutamate. This action of 6-OHDOPA has the potential of producing an adverse spectrum of action when 6-OHDOPA is used as a selective noradrenergic neurotoxin. In summary, 6-OHDOPA has proven useful in defining elements of noradrenergic neuronal neurotoxicity, and for uncovering the sprouting potential of locus coeruleus neurons following perinatal damage.
Abbreviations
- 5-HT:
-
5-hydroxytryptamine
- 6-OHDA:
-
6-hydroxydopamine
- 6-OHDOPA:
-
6-hydroxydopa
- BBB:
-
Blood–brain barrier
- CNS:
-
Central nervous system
- DA:
-
Dopamine
- icv:
-
Intracerebroventricular
- ip:
-
Intraperitoneal
- MK-485:
-
N-(DL-seryl)‘N’-2,3,4-trihydroxybenzylhydrazine
- MK-801:
-
Dizocilpine; 5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine
- NE:
-
Norepinephrine
- NET:
-
Norepinephrine transporter
- NMDA:
-
N-methyl-D-aspartate
- sc:
-
Subcutaneous
References
Aizenman, E., White, W. F., Loring, R. H., & Rosenberg, P. A. (1990). A 3,4-dihydroxyphenylalanine oxidation product is a non-N-methyl-D-aspartate glutamatergic agonist in rat cortical neurons. Neuroscience Letters, 116, 168–171. https://doi.org/10.1016/0304-3940(90)90404-w. PMID: 1979663.
Aizenman, E., Boeckman, F. A., & Rosenberg, P. A. (1992). Glutathione prevents 2,4,5-trihydroxyphenylalanine excitotoxicity by maintaining it in a reduced, non-active form. Neuroscience Letters, 144, 233–236. https://doi.org/10.1016/0304-3940(92)90757-x. PMID: 1436708.
Berkowitz, B. A., Spector, S., Brossi, A., Focella, A., & Teitel, S. (1970). Preparation and biological properties of (−)- and (+)-6-hydroxydopa. Experientia, 26, 982–983. https://doi.org/10.1007/BF02114144. PMID: 5478645.
Biscoe, T. J., Evans, R. H., Headley, P. M., Martin, M. R., & Watkins, J. C. (1976). Structure-activity relations of excitatory amino acids on frog and rat spinal neurons. British Journal of Pharmacology, 58, 373–382. https://doi.org/10.1111/j.1476-5381.1976.tb07714.x. PMID: 990592.
Cha, J. H., Dure, L. S., IV, Sakurai, S. Y., Penney, J. B., & Young, A. B. (1991). 2,4,5-Trihydroxyphenylalanine (6-hydroxy-dopa) displaces [3H]AMPA binding in rat striatum. Neuroscience Letters, 132, 55–58. https://doi.org/10.1016/0304-3940(91)90432-s. PMID: 1664920.
Clark, M. B., King, J. C., & Kostrzewa, R. M. (1979). Loss of nerve cell bodies in caudal locus coeruleus following treatment of neonates with 6-hydroxydopa. Neuroscience Letters, 13, 331–336. https://doi.org/10.1016/0304-3940(79)91515-5. PMID: 530483.
Clarke, D. E., Smookler, H. H., Hadinata, J., Chi, C., & Barry, H., 3rd. (1972). Acute effects of 6-hydroxyDOPA and its interaction with DOPA on brain amine levels. Life Sciences, 11, 97–102. https://doi.org/10.1016/0024-3205(72)90222-6. PMID: 4653197.
Harston, C. T., Morrow, A., & Kostrzewa, R. M. (1980). Enhancement of sprouting and putative regeneration of central noradrenergic fibers by morphine. Brain Research Bulletin, 5, 421–424. https://doi.org/10.1016/s0361-9230(80)80012-8. PMID: 7407638.
Harston, C. T., Clark, M. B., Hardin, J. C., & Kostrzewa, R. M. (1981). Opiate-enhanced toxicity and noradrenergic sprouting in rats treated with 6-hydroxydopa. European Journal of Pharmacology, 71, 365–373. https://doi.org/10.1016/0014-2999(81)90180-1. PMID: 6788574.
Harston, C. T., Clark, M. B., Hardin, J. C., & Kostrzewa, R. M. (1982). Developmental localization of noradrenergic innervation to the rat cerebellum following neonatal 6-hydroxydopa and morphine treatment. Developmental Neuroscience, 5, 252–262. https://doi.org/10.1159/000112683. PMID: 6813097.
Jacobowitz, D., & Kostrzewa, R. (1971). Selective action of 6-hydroxydopa on noradrenergic terminals: Mapping of preterminal axons of the brain. Life Sciences I, 10, 1329–1342. https://doi.org/10.1016/0024-3205(71)90333-x. PMID: 5144293.
Jaim-Etcheverry, G., Teitelman, G., & Zieher, L. M. (1975). Choline acetyltransferase activity increases in the brain stem of rats treated at birth with 6-hydroxydopa. Brain Research, 100, 699–704. https://doi.org/10.1016/0006-8993(75)90172-9. PMID: 1192203.
Jonsson, G., & Sachs, C. (1973). Pharmacological modifications of the 6-hydroxy-dopa induced degeneration of central noradrenaline neurons. Biochemical Pharmacology, 22, 1709–1716. https://doi.org/10.1016/0006-2952(73)90384-5. PMID: 4715992.
Klisans-Fuenmayor, D., Harston, C. T., & Kostrzewa, R. M. (1986). Alterations in noradrenergic innervation of the brain following dorsal bundle lesions in neonatal rats. Brain Research Bulletin, 16, 47–54. https://doi.org/10.1016/0361-9230(86)90011-0. PMID: 3082466.
Kostrzewa, R. M. (1975). Effects of neonatal 6-hydroxydopa treatment on monamine content of rat brain and peripheral tissues. Research Communications in Chemical Pathology & Pharmacology, 11, 567–579. PMID: 1179028.
Kostrzewa, R. M. (1988). Reorganization of noradrenergic neuronal systems following neonatal chemical and surgical injury. Progress in Brain Research, 73, 405–423. https://doi.org/10.1016/S0079-6123(08)60518-X. PMID: 3138742. Review.
Kostrzewa, R. M. (2016). Perinatal lesioning and lifelong effects of the noradrenergic neurotoxin 6-hydroxydopa. Current Topics in Behavioral Neuroscience, 29, 43–50. https://doi.org/10.1007/7854_2015_414. PMID: 26660536. Review.
Kostrzewa, R. M., & Brus, R. (1998). Destruction of catecholamine-containing neurons by 6-hydroxydopa, an endogenous amine oxidase cofactor. Amino Acids, 14, 175–179. https://doi.org/10.1007/BF01345259. PMID: 9871458. Review.
Kostrzewa, R. M., & Garey, R. E. (1976). Effects of 6-hydroxydopa on noradrenergic neurons in developing rat brain. Journal of Pharmacology and Experimental Therapeutics, 197, 105–118. PMID: 1263125.
Kostrzewa, R. M., & Garey, R. E. (1977). Sprouting of noradrenergic terminals in rat cerebellum following neonatal treatment with 6-hydroxydopa. Brain Research, 124, 385–391. https://doi.org/10.1016/0006-8993(77)90898-8. PMID: 843956.
Kostrzewa, R. M., & Harper, J. W. (1974). Effect of 6-hydroxydopa on catecholamine-containing neurons in brains of newborn rats. Brain Research, 69, 174–181. https://doi.org/10.1016/0006-8993(74)90386-2. PMID: 4817911.
Kostrzewa, R., & Jacobowitz, D. (1972). The effect of 6-hydroxydopa on peripheral adrenergic neurons. Journal of Pharmacology & Experimental Therapeutics, 183, 284–297. PMID: 5083546.
Kostrzewa, R., & Jacobowitz, D. (1973). Acute effects of 6-hydroxydopa on central monoaminergic neurons. European Journal of Pharmacology, 21, 70–80. https://doi.org/10.1016/0014-2999(73)90209-4. PMID: 4709209.
Kostrzewa, R. M., & Klisans-Fuenmayor, D. (1984). Development of an opioid-specific action of morphine in modifying recovery of neonatally-damaged noradrenergic fibers in rat brain. Research Communications in Chemical Pathology & Pharmacology, 46, 3–11. PMID: 6438742.
Künig, G., Hartmann, J., Niedermeyer, B., Deckert, J., Ransmayr, G., Heinsen, H., Beckmann, H., & Riederer, P. (1994). Excitotoxins L-beta-oxalyl-amino-alanine (L-BOAA) and 3,4,6-trihydroxyphenylalanine (6-OH-DOPA) inhibit [3H] alpha-amino-3- hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) binding in human hippocampus. Neuroscience Letters, 169, 219–222. https://doi.org/10.1016/0304-3940(94)90396-4. PMID: 7914016.
Newcomer, T. A., Palmer, A. M., Rosenberg, P. A., & Aizenman, E. (1993). Nonenzymatic conversion of 3,4-dihydroxyphenylalanine to 2,4,5-trihydroxyphenylalanine and 2,4,5-trihydroxyphenylalanine quinone in physiological solutions. Journal of Neurochemistry, 61, 911–920. https://doi.org/10.1111/j.1471-4159.1993.tb03602.x. PMID: 8360690.
Nomura, Y., & Segawa, T. (1978a). Apomorphine-induced locomotor stimulation in developing rats treated with 6-hydroxydopa. European Journal of Pharmacology, 50, 153–156. https://doi.org/10.1016/0014-2999(78)90012-2. PMID 679980.
Nomura, Y., & Segawa, T. (1978b). Muscarinic hyposensitivity in the developing rat pretreated with 6-hydroxydopa. European Journal of Pharmacology, 50, 431–435. https://doi.org/10.1016/0014-2999(78)90149-8. PMID: 568070.
Nomura, Y., & Segawa, T. (1979). Striatal dopamine content reduced in developing rats treated with 6-hydroxydopa. Japan Journal of Pharmacology, 29, 306–309. https://doi.org/10.1254/jjp.29.306. PMID: 537253.
Nomura, Y., Kajiyama, H., & Segawa, T. (1979a). Decrease in muscarinic cholinergic response of the rat heart following treatment with 6-hydroxydopa. European Journal of Pharmacology, 60, 323–327. https://doi.org/10.1016/0014-2999(79)90236-x. PMID: 527668.
Nomura, Y., Kajiyama, H., Nakata, Y., & Segawa, T. (1979b). Muscarinic cholinergic binding in striatal and mesolimbic areas of the rat: Reduction by 6-hydroxydopa. European Journal of Pharmacology, 58, 125–131. https://doi.org/10.1016/0014-2999(79)90003-7. PMID: 499342.
Olney, J. W., Zorumski, C. F., Stewart, G. R., Price, M. T., Wang, G. J., & Labruyere, J. (1990). Excitotoxicity of L-dopa and 6-OH-dopa: Implications for Parkinson’s and Huntington’s diseases. Experimental Neurology, 108, 269–272. https://doi.org/10.1016/0014-4886(90)90134-e. PMID: 1972067.
Ong, H. H., Creveling, C. R., & Daly, J. W. (1969). The synthesis of 2,4,5-trihydroxyphenylalanine (6-hydroxydopa). A centrally active norepinephrine-depleting agent. Journal of Medicinal Chemistry, 12, 458–462. https://doi.org/10.1021/jm00303a028. PMID: 5788162.
Porter, C. C., Totaro, J.A., & Stone, C. A. (1963). Effects of 6-hydroxydopamine and some other compounds on the concentration of nerepinephrine in the hearts of mice. Journal of Pharmacology and Experimental Therapeutics, 140, 308–316.
Richardson, J. S., & Jacobowitz, D. M. (1973). Depletion of brain norepinephrine by intraventricular injection of 6-hydroxydopa: A biochemical, histochemical and behavioral study in rats. Brain Research, 58, 117–133. https://doi.org/10.1016/0006-8993(73)90827-5. PMID: 4740976.
Rosenberg, P. A., Loring, R., Xie, Y., Zaleskas, V., & Aizenman, E. (1991). 2,4,5-trihydroxyphenylalanine in solution forms a non-N-methyl-D-aspartate glutamatergic agonist and neurotoxin. Proceedings of the National Academy of Sciences of the United States of America, 88, 4865–4869. https://doi.org/10.1073/pnas.88.11.4865. PMID: 1675790.
Sachs, C., & Jonsson, G. (1972a). Selective 6-hydroxy-DOPA induced degeneration of central and peripheral noradrenaline neurons. Brain Research, 40, 563–568. https://doi.org/10.1016/0006-8993(72)90163-1. PMID: 5027179.
Sachs, C., & Jonsson, G. (1972b). Degeneration of central and peripheral noradrenaline neurons produced by 6-hydroxy-DOPA. Journal of Neurochemistry, 19, 1561–1575. https://doi.org/10.1111/j.1471-4159.1972.tb05100.x. PMID: 5035304.
Sachs, C., & Jonsson, G. (1973). Pharmacological modifications of the 6-hydroxy-dopa induced degeneration of central noradrenaline neurons. Biochemical Pharmacology, 22, 1709–1716. https://doi.org/10.1016/0006-2952(73)90384-5. PMID: 4715992.
Sachs, C., Jonsson, G., & Fuxe, K. (1973). Mapping of central noradrenaline pathways with 6-hydroxy-DOPA. Brain Research, 63, 249–261. https://doi.org/10.1016/0006-8993(73)90092-9. PMID: 4764299.
Stone, C. A., Stavorski J. M., Ludden, C. T., Wenger H. C., Ross, C. A., Totaro, J. A., & Porter, C. C. (1963) Comparison of some pharmacologic effects of certain 6-substituted dopamine derivatives with reserpine, guanethidine and metaraminol. Journal of Pharmacology and Experimental Therapeutics, 142, 147–156.
Thoenen, H., & Tranzer J. P. (1968) Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn-Schmiedebergs Archiv fur Experimentelle Pathologie und Pharmakologie, 261, 271–288.
Ungerstedt, U. (1968) 6-Hydroxy-dopaamine induced degeneration of central monoamine neurons. The European Journal of Pharmacology, 5, 107–110.
Zieher, L. M., & Jaim-Etcheverry, G. (1973). Regional differences in the long-term effect of neonatal 6-hydroxydopa treatment on rat brain noradrenaline. Brain Research, 60, 199–207. https://doi.org/10.1016/0006-8993(73)90858-5. PMID: 4744760.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Kostrzewa, R.M. (2021). 6-Hydroxydopa: A Precursor-Neurotoxin with Relative Selectivity for Noradrenergic Neurons. In: Kostrzewa, R.M. (eds) Handbook of Neurotoxicity. Springer, Cham. https://doi.org/10.1007/978-3-030-71519-9_187-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-71519-9_187-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71519-9
Online ISBN: 978-3-030-71519-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences